Dossier assessment

Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A21-117
Last updated

Report documents

  1. Extract of dossier assessment

    Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 409 kB, EN, not accessible
  2. Dossier assessment

    Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 559 kB, DE, not accessible

Dossier assessment

Indication:

Adults with symptomatic anaemia associated with chronic kidney disease (CKD) who were not previously treated with an erythropoiesis-stimulating agent (ESA) or who are converting from an ESA (conversion of adults with stable ESA pretreatment only when there is a medical indication for a treatment switch)

Result of dossier assessment:

Added benefit not proven.

Project details

Project no.
A21-117
Commission
Commission awarded on 06.09.2021 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Haematology
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form